A PHASE 1, OPEN-LABEL, RANDOMIZED, 3-PERIOD, 6-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOAVAILABILITY OF BOSUTINIB ADMINISTERED AS CAPSULE CONTENTS MIXED WITH APPLESAUCE OR YOGURT RELATIVE TO INTACT CAPSULES IN HEALTHY PARTICIPANTS UNDER FED CONDITION
Latest Information Update: 15 Feb 2022
At a glance
- Drugs Bosutinib (Primary)
- Indications Amyotrophic lateral sclerosis; Chronic myeloid leukaemia; Glioblastoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Pfizer
- 09 Feb 2022 Status changed from active, no longer recruiting to completed.
- 18 Jan 2022 Planned End Date changed from 21 Dec 2021 to 11 Feb 2022.
- 18 Jan 2022 Planned primary completion date changed from 21 Dec 2021 to 11 Feb 2022.